Signal

Industry briefings on technology, evidence and the decisions ahead.

Meta’s Muse agent began completing purchases for U.S. shoppers through Stripe, PayPal and Shop Pay, Amazon blocked it, and a federal appeals court weakened the legal basis for keeping such agents out. In freight, C.H. Robinson again reported higher profit with fewer people, while a verdict of more than $600 million and repriced broker insurance changed what carrier and driver records need to show.
Read the briefing
Energy · Q3 2026

Grid operators and states put conditions on new data-center load in Q3 2026

Editorial snapshot: 31 October 2026
Utilities, grid operators and their regulators spent the quarter separating data-center demand that will arrive from requests that may not, and deciding who pays for the supply it needs. Inside energy companies, AI stayed mostly at the pilot stage and in vendor-reported task results, and New York ordered its utilities to inventory every use.
Read the briefing
Financial services · Q3 2026

AI pressure on financial firms shifted to customer accounts and cyber defenses

Editorial snapshot: 31 October 2026
Banks, insurers and asset managers now run AI agents for code, operations and adviser support under tightening permissions. In the third quarter, new pressure came from outside those programs: consumer agents that read customers’ bank data and buy on their behalf, and frontier models that find software flaws faster than firms fix them.
Read the briefing
Healthcare · Q3 2026

EHR vendors built AI into documentation, coding and prior authorization

Editorial snapshot: 31 October 2026
For health systems, physician practices and payers, AI now arrives inside the EHR and revenue-cycle platforms they already run. The quarter’s strongest study found that an ambient scribe raised the volume and intensity of physicians’ billed work, and payers, states and Medicare are now contesting where that gain belongs.
Read the briefing
Life sciences and pharma · Q3 2026

AI moved into pharma’s R&D and trial systems while the clinical evidence stayed early

Editorial snapshot: 31 October 2026
Frontier AI labs and established software vendors sold agents into discovery, clinical operations and regulated content in the third quarter of 2026. They did so as US tariffs and most-favored-nation pricing deals pressed on revenue per drug, with more than $500 billion of worldwide sales at risk from loss of exclusivity through 2032.
Read the briefing
After OpenAI scaled back in-chat checkout in March, Google, Visa, Mastercard and Stripe spent the second quarter building carts, credentials and purchase mandates that let AI agents shop while the retailer stays merchant of record. In freight and fulfillment, the reported results came from C.H. Robinson, Walmart and Amazon applying AI inside operations they already control.
Read the briefing
In the second quarter, utilities, grid operators and state commissions worked to separate data-center load that will arrive from load that has only been requested, while gas-turbine makers raised prices on the equipment that new supply depends on, with lead times of about three years. Inside the industry, AI reached a regulated workflow at PJM, where its effect has yet to be measured.
Read the briefing
Health systems, practices and payers spent the second quarter finding out what ambient documentation and prior-authorization automation return. A five-system JAMA study measured the time saved, UnitedHealthcare tied rising costs to provider billing and AI revenue-cycle tools, at least 10 states enacted AI-in-health laws and Congress challenged Medicare's AI prior-authorization model.
Read the briefing
Financial services · Q1 2026

Large financial firms moved AI agents into back-office operations in Q1 2026

Editorial snapshot: 30 April 2026
Banks, insurers and card networks spent the first quarter assigning AI agents to trade accounting, client onboarding, claims intake and payments, mostly in testing or narrow deployments. For operations, risk and technology leaders, the open questions concern what those agents can touch, how supervisors will see their work and where the savings go.
Read the briefing
Between January and March, Epic made ambient documentation a built-in EHR feature; OpenAI began selling products built for HIPAA-covered work to health systems, and Anthropic to providers and payers; and traditional Medicare began AI-assisted prior authorization in six states. The tools now sit inside the systems that produce notes, codes and authorization requests, so their effects reach payers as well as clinicians.
Read the briefing
Shares of Thomson Reuters, RELX and Wolters Kluwer fell 10.5% to 18% on Feb. 3 after Anthropic released a free legal plug-in, and by Feb. 25 LexisNexis and Thomson Reuters had both announced plans to build on Anthropic's technology. For firms and legal departments, the quarter brought broad AI use with little change in pricing or policy, and courts that began enforcing the duty to verify what is filed.
Read the briefing
Life sciences and pharma · Q1 2026

Pharma's AI money went to compute and preclinical licenses as FDA and EMA set joint principles

Editorial snapshot: 30 April 2026
Large drug companies, with more than $330 billion of revenue facing loss of exclusivity over the next five years, spent the first quarter of 2026 buying late-stage assets. Their AI commitments arrived as compute, milestone-heavy discovery licenses and agents inside existing software, while U.S. and European regulators began defining what AI-supported evidence must show.
Read the briefing

Start a conversation

Have a project in mind, or just exploring an idea? Let’s talk.
Fill out the form or give us a call.

413-570-3299

What can we help you with?